Stock MDXH MDXHEALTH SA
Add to a list
To use this feature you must be a member
Log inSign up

Ratings MDxHealth SA

Equities

MDXH

BE0974461940

Market Closed - Nasdaq
Other stock markets
 21:00:00 17/05/2024 BST 		5-day change 1st Jan Change
2.88 USD +0.70% Intraday chart for MDxHealth SA +3.97% -26.90%
05-01 MDxHealth SA Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-01 Transcript : MDxHealth SA, Q1 2024 Earnings Call, May 01, 2024

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 61% by 2026.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
MDXHEALTH SA Stock MDxHealth SA
-26.90% 78.59M - -
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.09% 42.12B
B
LONZA GROUP AG Stock Lonza Group AG
+49.62% 42.05B
A
CELLTRION, INC. Stock Celltrion, Inc.
-4.96% 29.18B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.18% 26.02B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.95% 18.9B
B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+8.61% 13.21B
B+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.73% 12.17B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.31% 12.16B
C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-6.26% 11.42B
C+
Investor Rating
-
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. MDXH Stock
  4. Ratings MDxHealth SA